

1 **SARS-Cov-2 Viral Load as an Indicator for COVID-19 Patients' Hospital**  
2 **Stay**

3 Salman Al Ali<sup>1</sup>, AbdulKarim AbdulRahman<sup>2</sup>, Omar Yaghi<sup>3</sup>, Essam M. Janahi<sup>4</sup>, Manaf Al-  
4 Qahtani<sup>1, 5, 6,\*</sup>

5

6 **Short title** Viral load and length of hospital stay

7 <sup>1</sup>Bahrain National Taskforce to Combat COVID-19, Bahrain Defense Force Hospital, Bahrain.

8 <sup>2</sup>Bahrain National Taskforce to Combat COVID-19, Mohammed bin Khalifa Cardiac Centre,  
9 Bahrain.

10 <sup>3</sup>Bahrain National Taskforce to Combat COVID-19, Bahrain.

11 <sup>4</sup>Independent Researcher, Building 1848, Road 7542, Al Janabiyah 0575, Northern Governorate,  
12 Bahrain.

13 <sup>5</sup>Consultant Infectious disease and clinical microbiologist, Bahrain Defense Force hospital,  
14 Bahrain.

15 <sup>6</sup>Associate Professor in Microbiology at Royal College of Surgeons in Ireland, Bahrain.

16

17

18 **\*Corresponding author:**

19 Manaf M. Al-Qahtani

20 Consultant Infectious disease and clinical microbiologist, Bahrain Defense Force hospital,  
21 Bahrain

22 Email: [mqahtani@rcsi-mub.com](mailto:mqahtani@rcsi-mub.com)

23

24

25

26 **Abstract**

27 **Background/objective:** The novel coronavirus disease 2019 (COVID-19) pandemic poses a  
28 global threat to the public health. There is a challenge in measuring the patient's length of  
29 hospital stay and managing the healthcare resources to handle the situation successfully. Our  
30 objective is to use the qPCR cycle of threshold (Ct) as a tool in evaluating the severity of the  
31 infection and hence the length of hospital stay to better utilize and manage the healthcare  
32 resources.

33 **Methods:** This cross sectional study was carried out on 306 patients who admitted to COVID-19  
34 care centers in Kingdom of Bahrain from 20<sup>th</sup> March 2020 to 5<sup>th</sup> April 2020. Standard qPCR was  
35 used to estimate the viral load and data were analyzed to investigate the relationship between Ct  
36 values and various variables.

37 **Results:** Out of 306 patients, 2 deaths, 1 active stable case and 303 recovered cases were  
38 reported. Ct value was significantly and negatively associated (P value <0.001) with length of  
39 hospital stay. The viral clearance was also inversely associated with the Ct values.

40 **Conclusion:** Ct value was inversely associated with hospital stay duration (and time to viral  
41 clearance), higher the Ct value is indicative of faster time to viral clearance. This association  
42 could help to better manage the infection and resources allocation.

43 **Keywords:** COVID-19; SARS-CoV-2; cycle of threshold; viral clearance; length of hospital stay

44

45

46

47

48

49

50

51

## 52 **Introduction**

53 Coronavirus disease 2019 (COVID-19) is caused by the newly identified strain of the  
54 Coronavirus family Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) <sup>1</sup>. Whilst  
55 some patients may have mild symptoms, others develop a severe respiratory distress syndrome  
56 with features of a blood coagulopathy requiring intensive support <sup>2</sup>. As a result, COVID-19 has  
57 rapidly evolved into a pandemic that has put a severe burden on the healthcare services of some  
58 countries, notably beds for both hospitalization and intensive care facilities <sup>3</sup>. Testing aids case  
59 identification, case isolation and contact tracing, all of which are vital to limit coronavirus spread  
60 <sup>4</sup>. Currently, the main diagnostic test for SARS-CoV-2 is the real-time Reverse Transcription  
61 Polymerase Chain Reaction (RT-PCR) <sup>5</sup>. The RT-PCR result is influenced by the Cycle  
62 Threshold (Ct-Value) that has been suggested as a quantitative test to indirectly assess the viral  
63 load <sup>6</sup> with severe cases having a much higher viral load than mild cases <sup>7</sup>. Therefore, the aim of  
64 this study was to measure the viral load determined by the Ct value and relate that to viral  
65 clearance to determine if this could predict length of hospital stay, as that may help guide  
66 healthcare resource allocation.

## 67 **Methods**

### 68 **Patients and Sample Collection**

69 A cross sectional study was undertaken on 306 patients who were admitted to COVID-19 care  
70 centers in the Kingdom of Bahrain between March 20<sup>th</sup>, 2020 and April 5<sup>th</sup>, 2020. Of those 306  
71 patients, 303 had recovered from their COVID-19 disease. Data were recorded for  
72 demographics, Ct-value on admission, time to viral clearance, and data on the length of stay and  
73 patient outcomes. At the time of the study, the local protocol in Bahrain admits all positive cases  
74 to treatment/isolation facilities regardless of being symptomatic or asymptomatic. The patients  
75 are discharged when they have two negative nasopharyngeal and oropharyngeal swabs on two  
76 consecutive days. All admitted patients are tested after three days of being asymptomatic and, if  
77 negative, the test is repeated after 24 hours to confirm viral clearance, following which the  
78 patients are discharged. Therefore, the length of stay was the same as the time to viral clearance  
79 and the minimum stay of patients is four days.

80

## 81 **RNA Extraction and SARS-Cov-2 RNA Amplification**

82 The diagnostic test used for SARS-CoV-2 was performed using qPCR on nasopharyngeal and  
83 oropharyngeal samples. The samples were transferred to a viral transport media immediately  
84 after collection and transported to a COVID-19 laboratory for testing. Diagnosed cases were a  
85 heterogeneous sample of tested patients, they included symptomatic and asymptomatic  
86 individuals with recent exposure to a confirmed COVID19 case or travelers arriving from high  
87 risk countries. PCR test was conducted using Thermo Fisher Scientific (Waltham, MA) TaqPath  
88 1-Step RT-qPCR Master Mix, CG on the Applied Biosystems (Foster City, CA) 7500 Fast Dx  
89 RealTime PCR Instrument. The assay used followed the WHO protocol from Charité Virology,  
90 Berlin, Germany <sup>8</sup>. and targeted the E gene. If the E gene was detected, the sample was then  
91 confirmed by RdRP and N genes. The E gene CT value was reported and used in this study. CT  
92 Values >40 were considered negative. Positive and negative controls were included for quality  
93 control purposes.

## 94 **RT-qPCR Analytical Validation**

95 Linear range was determined using serial log<sub>10</sub> dilutions of standard RNA and was established  
96 between  $3.5 \times 10^3$  to  $3.5 \times 10^{12}$  copies of RNA/mL, with amplification efficiency of 87% and  
97 with a regression R<sup>2</sup> value higher than 0.99.

## 98 **Statistical Analysis**

99 Categorical parameters were expressed as frequencies (%), whereas continuous variables are  
100 presented as mean. Data trends were visually and statistically evaluated for normality. We used  
101 regression analysis to describe the relationship between categorical variables and between  
102 continuous variables with the main outcome. Two-way Student's t test was then used to detect  
103 the difference between Ct values across symptomatic and asymptomatic individuals. Statistical  
104 analysis was performed using STATA statistical computer package (StataCorp. 2013. Stata  
105 Statistical Software).

## 106 **Ethical Approval**

107 The protocol and manuscript for this study were reviewed and approved by the National COVID-  
108 19 Research and Ethics Committee in Bahrain (Approval code: CRT-COVID2020-004). This

109 committee has been jointly established by the Ministry of Health and Bahrain Defense Force  
110 Hospital research and ethical committees in response to the pandemic, to facilitate and monitor  
111 COVID-19 research in Bahrain. All methods and retrospective analysis of data was approved by  
112 the National COVID-19 Research and Ethics Committee, and carried out in accordance with the  
113 local guideline and ethical guidelines of the Declaration of Helsinki 1975. Informed consent was  
114 waived by the National COVID-19 Research and Ethical Committee for this study due to its  
115 retrospective and observational nature and the absence of any patient identifying information

## 116 **Results**

117 Of the 306 patients, there were 303 who had recovered, whilst 2 deaths and 1 active stable case  
118 were excluded from the analysis.

119 The descriptive summary of the patients is shown in Table 1. The sample of patients included  
120 cases who arrived in Bahrain from other countries, all travelers being tested upon arrival, and  
121 included cases of local spread. Initially, gender distribution of COVID-19 cases in Bahrain was  
122 equal; however, as the infection started to spread within the community of labor workers, who  
123 are mainly males, the ratio of males to females and the ratio of local cases to cases coming from  
124 other countries increased. Symptomatic patients were 12.2% of the sample, which corresponded  
125 to a similar percentage of the symptomatic patients in the entire population.

126 Ct values showed a statistically significant negative correlation of 0.28 with the length of  
127 hospital stay and time to viral clearance as seen in Figure 1 showing the Lowess smoothing curve  
128 of hospital stay. Higher Ct values on admission predicted shorter hospital stays and shorter time  
129 to clear the virus. The regression analysis showed similar results when using a univariate  
130 analysis and a multivariate analysis adjusted for age and gender. Ct value had a significant  
131 inverse correlation with the length of stay, 10 points higher on the Ct value correlating with a  
132 shorter hospital stay of 2.8 days.

133 Patients with high Ct values defined as  $\geq 35$  had shorter hospital stays, by 4.3 days, when  
134 compared to patients with Ct values  $< 35$  on admission.

135 The regression analysis for Length of Stay using Ct value as a covariate is shown in Table 2.  
136 Analysis on symptomatic individuals showed that symptomatic individuals have a lower mean Ct  
137 value when compared to asymptomatic individuals. Asymptomatic individuals had a mean Ct

138 value of 27.8. Symptomatic individuals had a mean Ct value of 25.5. A Two sample T-test  
139 showed a difference of 2.58 units in the mean Ct value between symptomatic and asymptomatic  
140 patients (Table 3).

## 141 **Discussion**

142 This study has shown that the higher the Ct values, the more rapid the viral clearance, leading to  
143 a shorter length of stay in hospital. A Ct value  $>35$  predicted a shorter hospital stay by 4.3 days,  
144 and a 10 unit increase in Ct value was associated with a shortened time to viral clearance of 2.8  
145 days. Ct values have been reported as an indirect assessment of the viral load <sup>6,7</sup>, with higher Ct  
146 values having a lower viral load, and it has been shown that those patients with more severe  
147 disease have lower Ct values <sup>7</sup>. Higher Ct values indicate an early infection or a recovering  
148 infection. Whilst Ct values can be used to predict length of hospital stay for stable cases, the Ct  
149 value cannot, however, predict outcomes. Outcomes are influenced by many additional  
150 predictors, most notably comorbidities and severity of disease <sup>9</sup>. The presence of age greater than  
151 60 and comorbidities including diabetes, hypertension, obesity and respiratory disease may offset  
152 a high Ct values and further studies to predict outcomes based on Ct value taking into account  
153 adverse risk factors of disease severity are needed.

154 In this study, symptomatic individuals had lower Ct values whilst asymptomatic individuals had  
155 higher Ct values, suggesting that the lower Ct values reflects a more severe presentation.  
156 However, asymptomatic individuals still had a low mean Ct values (27.8) indicating a  
157 significant viral load, suggesting that asymptomatic individuals can still transmit the disease <sup>10</sup>.  
158 These results are in accord with those of Liu et al who reported that the mean viral load of severe  
159 cases was around 60 times higher than that of mild cases <sup>7</sup>. La Scola et. al have reported using  
160 cell culture system that patients with Ct values  $\geq 34$  do not shed infectious virions, and hence  
161 are not infectious and can be discharged from hospitals or care centers<sup>11</sup> .

162 Bahrain has pursued a comprehensive testing program with all travelers arriving in the country  
163 being tested, mobile screening services, random screening in high risk communities and  
164 extensive contact tracing. This strategy has resulted in detecting many asymptomatic patients, in  
165 contrast to other countries where the response has been directed solely towards symptomatic  
166 patients, and has generated data that is critical for production of accurate prediction models <sup>12</sup>.

167 Limitations of this study include that it was cross sectional and that the number of symptomatic  
168 cases were few in number. The number of patients with multiple comorbidities were few and  
169 therefore a model to take into account the protective effect of a high Ct value could not be  
170 determined.

## 171 **Conclusion**

172 In this current study it was evident that Ct value can predict the duration of hospital stay of  
173 COVID-19 infected patients, which also suggests that viral clearance will be faster in higher Ct  
174 value patients. This data can be implemented in other country to evaluate the patients stay at  
175 hospital and also helpful in managing the healthcare staff in successfully handling the COVID-  
176 19 infected patients.

177

178

179

180

181

182

183

184

185

186

187

188

## 189 **DECLARATIONS**

190 **Ethics approval and consent to participate:** The study was approved by the National Covid-19  
191 Research and Ethics Committee.

192 **Consent for publication:** Consent for publication was waived by the Ethical committee.

193 **Availability of data and materials:** All the data for this study will be made available upon  
194 reasonable request to the corresponding author.

195 **Funding:** No funding was received to perform this study.

196 **Conflict of interest:** The authors have declared that no conflict of interest exists.

197 **Author contributions:** SA, and OY analyzed the data and wrote the manuscript. AA, OY and  
198 SA contributed to study design, collected, analysed, and interpreted data and edited the  
199 manuscript. MA supervised data collection, data analysis and edited the manuscript. EMJ data  
200 interpretation and the editing of the manuscript. All authors reviewed and approved the final  
201 version of the manuscript. Manaf Alqahtani is the guarantor of this work.

202



## 203   **References**


- 204   1.     Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease  
205   (COVID-19) outbreak. *Journal of autoimmunity*. May 2020;109:102433.  
206   doi:10.1016/j.jaut.2020.102433
- 207   2.     Fogarty H, Townsend L, Ni Cheallaigh C, et al. COVID-19 Coagulopathy in Caucasian  
208   patients. *British journal of haematology*. Apr 24 2020;doi:10.1111/bjh.16749
- 209   3.     Carenzo L, Costantini E, Greco M, et al. Hospital surge capacity in a tertiary emergency  
210   referral centre during the COVID-19 outbreak in Italy. *Anaesthesia*. Apr 4  
211   2020;doi:10.1111/anae.15072
- 212   4.     Hellewell J, Abbott S, Gimma A, et al. Feasibility of controlling COVID-19 outbreaks by  
213   isolation of cases and contacts. *The Lancet Global health*. Apr 2020;8(4):e488-e496.  
214   doi:10.1016/s2214-109x(20)30074-7
- 215   5.     Udugama B, Kadhiresan P, Kozlowski HN, et al. Diagnosing COVID-19: The Disease  
216   and Tools for Detection. *ACS nano*. Apr 28 2020;14(4):3822-3835.  
217   doi:10.1021/acsnano.0c02624
- 218   6.     Zou L, Ruan F, Huang M, et al. SARS-CoV-2 Viral Load in Upper Respiratory  
219   Specimens of Infected Patients. *The New England journal of medicine*. Mar 19  
220   2020;382(12):1177-1179. doi:10.1056/NEJMc2001737
- 221   7.     Liu Y, Yan LM, Wan L, et al. Viral dynamics in mild and severe cases of COVID-19.  
222   *The Lancet Infectious diseases*. Mar 19 2020;doi:10.1016/s1473-3099(20)30232-2
- 223   8.     Corman VM, Landt O, Kaiser M, et al. Detection of 2019 novel coronavirus (2019-  
224   nCoV) by real-time RT-PCR. *Euro Surveill*. Jan 2020;25(3)doi:10.2807/1560-  
225   7917.Es.2020.25.3.2000045
- 226   9.     Bhatraju PK, Ghassemieh BJ, Nichols M, et al. Covid-19 in Critically Ill Patients in the  
227   Seattle Region - Case Series. *The New England journal of medicine*. Mar 30  
228   2020;doi:10.1056/NEJMoa2004500
- 229   10.    Furukawa NW, Brooks JT, Sobel J. Evidence Supporting Transmission of Severe Acute  
230   Respiratory Syndrome Coronavirus 2 While Presymptomatic or Asymptomatic. *Emerging*  
231   *infectious diseases*. May 4 2020;26(7)doi:10.3201/eid2607.201595
- 232   11.    La Scola B, Le Bideau M, Andreani J, et al. Viral RNA load as determined by cell culture  
233   as a management tool for discharge of SARS-CoV-2 patients from infectious disease wards. *Eur*  
234   *J Clin Microbiol Infect Dis*. Jun 2020;39(6):1059-1061. doi:10.1007/s10096-020-03913-9
- 235   12.    Wynants L, Van Calster B, Bonten MMJ, et al. Prediction models for diagnosis and  
236   prognosis of covid-19 infection: systematic review and critical appraisal. *Bmj*. Apr 7  
237   2020;369:m1328. doi:10.1136/bmj.m1328

238

239

240

241



242

243 Figure 1: Lowess smoothing curve plotting length of stay (days) vs qPCR Ct value on admission

244

245

246 Table 1: Characteristics of patients in the study

247

Variable		N	%
Gender	Male	215	71.0%
	Females	88	29.0%
Symptoms on Admission	Asymptomatic	266	87.8%
	Symptomatic	39	12.2%
Mode of Transmission	Local	194	64.0%
	Travel	109	36.0%
Nationality	Bahraini	177	58.4%
	Indian	89	29.4%
	Bangladeshi	19	6.3%
	Other	18	5.9%
Category of Ct values	Low : Ct<35	271	89.4%
	High : Ct>=35	32	10.6%
Variable	N	Mean	Range
Age (years)	303	37.1 ± 15.1	0 to 87
Ct value on Admission	303	27.5 ± 5.1	14.8 to 39
Length of Stay (days) (Time to viral clearance in Days)	303	11.3 ± 5.07	4 to 32

248

249

250 Table 2: Regression analysis for length of stay using Ct value as a covariate

251

Multivariate regression output, Adjusted for Age and Gender				
Outcome: Length of Stay in Days				
Continuous covariate	Coefficient	Standard Error	P value	95% Confidence Interval
Ct value	-0.28	.056	<0.001	-0.39 to -0.17
Multivariate regression output, Adjusted for Age and Gender				
Outcome: Length of Stay in Days				
Categorical covariate	Coefficient	Standard Error	P value	95% Confidence Interval
Low Ct value (<35)	-	-	-	
High Ct value (≥35)	-3.9	0.94	<0.001	-5.75 to -2.05

252

253

254

255 Table 3: Two sample t test comparing mean Ct values between symptomatic and asymptomatic  
256 individuals

Status	Mean Ct value	Standard Error	95% Confidence Interval
Asymptomatic	27.8	0.31	27.2 to 28.4
Symptomatic	25.5	0.82	23.9 to 27.8
Difference	2.3	0.88	0.6 to 4.0
P Value			0.01

257

258